Published in PLoS Pathog on May 10, 2012
A multifactorial role for P. falciparum malaria in endemic Burkitt's lymphoma pathogenesis. PLoS Pathog (2014) 1.58
Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event. Blood (2015) 1.44
The pathogenesis of Epstein-Barr virus persistent infection. Curr Opin Virol (2013) 1.33
Epstein-Barr virus and Burkitt lymphoma. Chin J Cancer (2014) 1.02
Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines. PLoS Pathog (2013) 1.01
Persistence of Epstein-Barr virus in self-reactive memory B cells. J Virol (2012) 0.93
Human viruses and cancer. Viruses (2014) 0.92
EBV finds a polycomb-mediated, epigenetic solution to the problem of oncogenic stress responses triggered by infection. Front Genet (2013) 0.91
The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease. Immunol Res (2014) 0.83
B cell infection and activation by rabies virus-based vaccines. J Virol (2013) 0.82
EBV Persistence-Introducing the Virus. Curr Top Microbiol Immunol (2015) 0.82
Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells. J Exp Med (2016) 0.81
Cytomegalovirus-seropositive children show inhibition of in vitro EBV infection that is associated with CD8+CD57+ T cell enrichment and IFN-γ. J Immunol (2013) 0.80
AID expression in peripheral blood of children living in a malaria holoendemic region is associated with changes in B cell subsets and Epstein-Barr virus. Int J Cancer (2014) 0.79
Repression of the proapoptotic cellular BIK/NBK gene by Epstein-Barr virus antagonizes transforming growth factor β1-induced B-cell apoptosis. J Virol (2014) 0.78
LMP1 and LMP2A collaborate to promote Epstein-Barr virus (EBV)-induced B cell lymphomas in a cord blood-humanized mouse model but are not essential. J Virol (2017) 0.75
Status of Epstein-Barr Virus Coinfection with Helicobacter pylori in Gastric Cancer. J Oncol (2017) 0.75
Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell (2000) 20.83
Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell (2000) 9.99
Clonal selection and learning in the antibody system. Nature (1996) 9.58
IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res (2008) 6.91
Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature (2001) 6.70
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A (1984) 6.62
The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell (1995) 5.97
Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol (2001) 5.08
EBV persistence in memory B cells in vivo. Immunity (1998) 4.44
Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol (1985) 3.76
AID mutant analyses indicate requirement for class-switch-specific cofactors. Nat Immunol (2003) 3.69
Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science (1991) 3.56
CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci U S A (2001) 3.54
Clonal transformation of adult human leukocytes by Epstein-Barr virus. J Virol (1977) 3.11
Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J (1997) 2.87
BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci U S A (1998) 2.76
Evidence for a large compartment of IgM-expressing memory B cells in humans. Blood (1997) 2.64
B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol (2003) 2.57
C-terminal deletion of AID uncouples class switch recombination from somatic hypermutation and gene conversion. Mol Cell (2003) 2.50
Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med (2002) 2.49
Human IgM+CD27+ B cells: memory B cells or "memory" B cells? J Immunol (2007) 2.26
An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe (2010) 2.23
Anti-CD40 monoclonal antibodies or CD4+ T cell clones and IL-4 induce IgG4 and IgE switching in purified human B cells via different signaling pathways. J Immunol (1991) 2.07
Variable region genes for the immunoglobulin framework are assembled from small segments of DNA--a hypothesis. Proc Natl Acad Sci U S A (1978) 1.92
CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+IgD+ B cell line. J Immunol (1998) 1.92
Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol (1997) 1.72
EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol (2003) 1.70
Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet (2003) 1.70
EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity (2000) 1.69
IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. J Immunol (2008) 1.68
Molecular footprints of a germinal center derivation of human IgM+(IgD+)CD27+ B cells and the dynamics of memory B cell generation. J Exp Med (2009) 1.61
Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia (1995) 1.58
High frequency of somatically mutated IgM molecules in the human adult blood B cell repertoire. Eur J Immunol (1992) 1.52
EBV persistence involves strict selection of latently infected B cells. J Immunol (2000) 1.50
Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM syndrome. J Clin Invest (1998) 1.48
Immunoglobulin heavy chain gene expression in peripheral blood B lymphocytes. J Clin Invest (1992) 1.46
Selective generation of functional somatically mutated IgM+CD27+, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease. J Clin Invest (2006) 1.44
Clonal instability of V region hypermutation in the Ramos Burkitt's lymphoma cell line. Int Immunol (2001) 1.36
Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proc Natl Acad Sci U S A (2005) 1.34
Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to cell outgrowth. J Gen Virol (2005) 1.30
Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation-inducing molecules and in the accrual of oncogene mutations. Mol Immunol (2006) 1.28
Epstein-Barr virus-infected B cells expanding in germinal centers of infectious mononucleosis patients do not participate in the germinal center reaction. Proc Natl Acad Sci U S A (2003) 1.26
Induction of germ-line and mature C epsilon transcripts in human B cells stimulated with rIL-4 and EBV. J Immunol (1990) 1.25
DNA polymerases in adaptive immunity. Nat Rev Immunol (2008) 1.22
Immunoregulatory role of CD40 in human B cell differentiation. J Immunol (1993) 1.20
Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood (2003) 1.19
Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus. Blood (2005) 1.18
Chromosomal rearrangements after ex vivo Epstein-Barr virus (EBV) infection of human B cells. Oncogene (2009) 1.16
IL-4 plus CD40 monoclonal antibody induces human B cells gamma subclass-specific isotype switch: switching to gamma 1, gamma 3, and gamma 4, but not gamma 2. J Immunol (1995) 1.13
Epstein-Barr virus-transformed human precursor B cell lines: altered growth phenotype of lines with germ-line or rearranged but nonexpressed heavy chain genes. Eur J Immunol (1987) 1.10
Activation-induced deaminase: light and dark sides. Trends Mol Med (2006) 1.08
Analysis of the targeting of the hypermutational machinery and the impact of subsequent selection on the distribution of nucleotide changes in human VHDJH rearrangements. Immunol Rev (1998) 1.08
EBV transformation overrides gene expression patterns of B cell differentiation stages. Mol Immunol (2008) 1.07
Molecular histogenesis of posttransplantation lymphoproliferative disorders. Blood (2003) 1.03
Epstein-Barr virus colonization of tonsillar and peripheral blood B-cell subsets in primary infection and persistence. Blood (2009) 1.00
Distinct ex vivo susceptibility of B-cell subsets to epstein-barr virus infection according to differentiation status and tissue origin. J Virol (2008) 0.97
Toll-like receptor agonists synergistically increase proliferation and activation of B cells by epstein-barr virus. J Virol (2010) 0.97
CD40 stimulation of human peripheral B lymphocytes: distinct response from naive and memory cells. J Immunol (2003) 0.97
BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression. Am J Pathol (1997) 0.95
Clonal evolution of lymphoblastoid cell lines. Lab Invest (2006) 0.93
Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes. Blood (2005) 0.93
Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. Hematol Oncol (2008) 0.90
Isotype commitment of human B cells that are transformed by Epstein-Barr virus. Eur J Immunol (1991) 0.90
B-lymphocyte subpopulations are equally susceptible to Epstein-Barr virus infection, irrespective of immunoglobulin isotype expression. Immunology (2003) 0.89
beta1 integrin expression increases susceptibility of memory B cells to Epstein-Barr virus infection. J Virol (2010) 0.88
Somatic mutations and activation-induced cytidine deaminase (AID) expression in established rheumatoid factor-producing lymphoblastoid cell line. Mol Immunol (2006) 0.84
Activation and targeting of immunoglobulin switch recombination by activities induced by EBV infection. J Immunol (1999) 0.83
Epstein-Barr virus (EBV)-positive lymphoproliferations in post-transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes. Eur J Immunol (2003) 0.83
In vitro triggering of somatic mutation in human naive B cells. J Immunol (1997) 0.83
Epstein-Barr virus can establish infection in the absence of a classical memory B-cell population. J Virol (2005) 0.82
Absence of immunoglobulin class switch in primary lymphomas of the central nervous system. Am J Pathol (2005) 0.81
Ongoing somatic hypermutation of the rearranged VH but not of the V-lambda gene in EBV-transformed rheumatoid factor-producing lymphoblastoid cell line. Mol Immunol (2008) 0.81
Anti-CD40 plus interleukin-4-activated human naive B cell lines express unmutated immunoglobulin genes with intraclonal heavy chain isotype variability. Eur J Immunol (1995) 0.81
Preferential targeting of somatic hypermutation to hotspot motifs and hypermutable sites and generation of mutational clusters in the IgVH alleles of a rheumatoid factor producing lymphoblastoid cell line. Mol Immunol (2010) 0.80
Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders. Br J Haematol (2004) 0.80
Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders. Hematol Oncol (2006) 0.78
Epstein-Barr virus: 40 years on. Nat Rev Cancer (2004) 9.70
Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science (2004) 5.10
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol (2007) 4.14
Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med (2002) 2.89
Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J Immunol (2004) 2.55
The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathog (2012) 2.45
Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol (2004) 2.11
Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet (2012) 2.07
Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med (2003) 2.01
A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J Immunol (2006) 1.98
The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nat Genet (2004) 1.82
Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst (2004) 1.80
Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood (2010) 1.75
The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc Natl Acad Sci U S A (2003) 1.75
Increased expression of the NK cell receptor KLRG1 by virus-specific CD8 T cells during persistent antigen stimulation. J Virol (2005) 1.74
A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med (2007) 1.70
Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet (2003) 1.70
Characterization and intracellular localization of the Epstein-Barr virus protein BFLF2: interactions with BFRF1 and with the nuclear lamina. J Virol (2005) 1.62
CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med (2005) 1.61
Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol (2006) 1.61
BFRF1 of Epstein-Barr virus is essential for efficient primary viral envelopment and egress. J Virol (2005) 1.59
Laminin-alpha4 and integrin-linked kinase mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells. Circulation (2007) 1.57
An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog (2009) 1.56
Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma. Leuk Lymphoma (2006) 1.51
A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus. PLoS Pathog (2011) 1.51
Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol (2005) 1.50
CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1. J Exp Med (2004) 1.47
Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. J Virol (2009) 1.31
The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog (2009) 1.31
Immune defence against EBV and EBV-associated disease. Curr Opin Immunol (2011) 1.31
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev (2014) 1.30
Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to cell outgrowth. J Gen Virol (2005) 1.30
BZLF1 activation of the methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186. J Virol (2005) 1.30
Expression and processing of a small nucleolar RNA from the Epstein-Barr virus genome. PLoS Pathog (2009) 1.28
Quantitative studies of Epstein-Barr virus-encoded microRNAs provide novel insights into their regulation. J Virol (2010) 1.27
Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP. PLoS Biol (2011) 1.27
Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci U S A (2006) 1.26
Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance. J Clin Invest (2005) 1.26
T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J Immunol (2007) 1.23
Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res (2002) 1.22
Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol (2005) 1.22
Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display. Proc Natl Acad Sci U S A (2010) 1.20
Selective accumulation of virus-specific CD8+ T cells with unique homing phenotype within the human bone marrow. Blood (2008) 1.19
Molecular genetics of DNA viruses: recombinant virus technology. Methods Mol Biol (2005) 1.18
Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program (2007) 1.17
Deletion of Epstein-Barr virus BFLF2 leads to impaired viral DNA packaging and primary egress as well as to the production of defective viral particles. J Virol (2008) 1.17
Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas. Cell Rep (2013) 1.17
Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. J Immunol (2009) 1.17
Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol (2009) 1.16
Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer (2002) 1.15
EBV tegument protein BNRF1 disrupts DAXX-ATRX to activate viral early gene transcription. PLoS Pathog (2011) 1.14
Epstein-Barr virus-specific CD8(+) T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential. Blood (2002) 1.13
Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog (2009) 1.11
The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes. J Virol (2011) 1.10
The BRRF1 early gene of Epstein-Barr virus encodes a transcription factor that enhances induction of lytic infection by BRLF1. J Virol (2004) 1.10
The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children. J Infect Dis (2009) 1.09
B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood (2002) 1.08
EBV-associated mononucleosis leads to long-term global deficit in T-cell responsiveness to IL-15. Blood (2006) 1.06
Marked variation in response of consensus binding elements for the Rta protein of Epstein-Barr virus. J Virol (2005) 1.05
Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood (2008) 1.05
Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity. J Virol (2005) 1.05
Epstein-Barr virus B95.8 produced in 293 cells shows marked tropism for differentiated primary epithelial cells and reveals interindividual variation in susceptibility to viral infection. Int J Cancer (2007) 1.04
Multiple Epstein-Barr virus strains in patients with infectious mononucleosis: comparison of ex vivo samples with in vitro isolates by use of heteroduplex tracking assays. J Infect Dis (2005) 1.04
Epstein-Barr virus and Burkitt lymphoma. Chin J Cancer (2014) 1.02
Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition. J Immunol (2011) 1.02
Mutation of a single amino acid residue in the basic region of the Epstein-Barr virus (EBV) lytic cycle switch protein Zta (BZLF1) prevents reactivation of EBV from latency. J Virol (2005) 1.02